Yazar "Gumusay, Ozge" için listeleme
-
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
Kahraman, Seda; Hizal, Mutlu; Demirel, Burcin Cakan; Guven, Deniz Can; Gumusay, Ozge; Uluc, Basak Oyan; Bayram, Ertugrul (Bmc, 2024)Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast ... -
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
Kahraman, Seda; Hizal, Mutlu; Gumusay, Ozge; Basaran, Gul; Seyyar, Mustafa; Sahin, Elif; Cabuk, Devrim (2025)Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for ... -
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
Dulgar, Ozgecan; Turker, Sema; Basaran, Gul; Araz, Murat; Sumbul, Ahmet Taner; Caglayan, Dilek; Gumusay, Ozge (Taylor & Francis Ltd, 2025)We aimed to evaluate the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab plus trastuzumab and taxane. We reviewed the medical records of patients ... -
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Kahraman, Seda; Erul, Enes; Gumusay, Ozge; Guven, Deniz Can; Aksoy, Sercan; Basaran, Gul; Seyyar, Mustafa (Cig Media Group, Lp, 2025)We conducted a multicenter, retrospective cohort study that included 522 patients with HR+/HER2-MBC treated with ribociclib or palbociclib in combination with fulvestrant. Although the three CDK4/6 inhibitors did not seem ...
